Johnson//Becker is now accepting lawsuits for individuals who were prescribed Dupixent (Dupilumab) and who developed Cutaneous T-Cell Lymphoma (CTCL) during or shortly after using the product.
Learn More: Do I Qualify to Participate in a Dupixent Lawsuit?
Studies Show Growing Concerns Over Dupixent Induced Cutaneous T-Cell Lymphoma
Studies are showing growing concerns regarding the risks associated with Dupixent, including an increased risk in developing T-Cell Lymphoma, (both Mycosis fungoides and Sezary syndrome,) a rare form of Hodgkin lymphoma, during and after using the medication. In addition, on March 31, 2025, the U.S. Food and Drug Administration (FDA) issued a Newly Identified Safety Signal (NISS) after analyzing adverse event data from the final quarter of 2024.This alert specifically noted a signal between Dupixent and CTCL.
Understanding the Connection Between Dupixent and CTCL
Recent studies have found that use of Dupilumab, (the active ingredient in Dupixent,) may cause increased risk of developing CTCL, or worsen its presence after the fact.
- A study released in 2020 suggests that Dupilumab worsens CTCL in patients who are already suffering from the illness.
- According to one study that was published in 2024 found that individuals who used Dupilumab were about 4.5 times more likely to develop CTCL than those who did not. As this study states, about 62% of those cases appeared within the first year of starting the routine prescription injection.
- A similar study published in 2024 had corresponding results in individuals with Eczema. These patients who used Dupixent were about 4 times more likely to be diagnosed with CTCL than those who did not, a majority of those cases having said to have appeared more than 1 year after starting the prescription drug.
- Case studies have found that CTCL may appear after using Dupixent in those prescribed regardless of age, sex, and ethnicity, although it may be more likely to commonly appear in those who are 60+
What is Dupixent?
Dupixent is a prescription medication containing the active ingredient, Dupilumab. The drug is administered through injection beneath the skin and is regularly prescribed to treat moderate to severe Eczema, moderate to severe Asthma, inflammation of the sinuses (Chronic Rhinosinusitis) with Nasal Polyps, Chronic Obstructive Pulmonary Disease (COPD,) and more.
What is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-Cell Lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma — a cancer that starts in the body’s immune system, specifically in T-cells, which are white blood cells that help fight infection.
What makes CTCL distinct is that instead of staying in the bloodstream or lymph nodes, the cancerous T-cells migrate to the skin, where they cause a variety of symptoms that can often look like common skin problems at first.
Symptoms of Dupixent And CTCL
In CTCL, certain T-cells become abnormal and begin to grow uncontrollably. These malignant T-cells gather in the skin and can cause:
- Persistent, itchy skin rashes that do not heal
- Dry, scaly, or thickened skin patches
- Plaques or raised areas that may resemble eczema or psoriasis
- Red or discolored patches of skin (often on the trunk, hips, or thighs)
- Skin tumors or nodules that may ulcerate
- Widespread redness or peeling of the skin (erythroderma)
- Swollen lymph nodes
- Hair loss or changes in the affected skin areas
- Thickened or cracked palms and soles
- Fatigue or unexplained weight loss (in advanced stages)
If you are taking Dupixent and suffering from any side effects, you should talk with your doctor or a healthcare professional immediately.
Main Subtypes of CTCL
Mycosis Fungoides: The most common form (about 50–70% of CTCL cases). It usually begins with flat, itchy skin lesions that can take years to progress.
Sézary Syndrome: A more aggressive form where cancerous T-cells are found in both the skin and the bloodstream, often causing widespread redness (erythroderma), scaling, and severe itching.
Do I Qualify to Participate in a Dupixent Lawsuit?
We are pursuing and currently accepting new Dupixent lawsuits for individuals who:
- Were taking Dupixent for 1+ months, and
- Were diagnosed with CTCL after using the medication.
Why Choose Johnson//Becker for Your Dupixent Lawsuit?
Johnson//Becker is dedicated to serving you or your family with care, compassion, and commitment. Our lawyers have significant legal qualifications and over two decades of experience to best represent your interests in matters of injury due to drug side effects like Dupixent and Cutaneous T-Cell Lymphoma.
Learn More: Why Choose Us
Questions About a Dupixent Lawsuit? Contact a Johnson//Becker Lawyer for a Free Case Review.
If you or a loved one were diagnosed with Cutaneous T-Cell Lymphoma after taking Dupixent, you may want to speak with the lawyers at Johnson//Becker. We are currently accepting Dupixent lawsuits nationwide, and you may be entitled to financial compensation.
We offer a Free Case Evaluation. Please contact us using the form below or by calling us at (800) 279-6386.
We would be honored to speak with you and respond promptly to every inquiry we receive.
Free Case Evaluation
To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (800) 279-6386.